MedTrace Logo

Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type I

NCT06852612 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-12

No results posted yet for this study

Summary

The present project will specifically assess metabolic effects of dietary interventions with controlled intake of fructose and fructose/galactose in GSDI, with the aim to provide evidence whether relaxed dietary restrictions of fructose and galactose may be justified in treatment recommendations at least for adults, which would considerably enlarge food choice in everyday life of the patients with an expected positive impact on the quality of life of patients with this rare disorder.

Conditions

  • Glycogen Storage Disease Type I

Interventions

DIETARY_SUPPLEMENT

Fructose

40g fructose (free and bound, max amount of fructose from added free sugar/saccharose 25g)

DIETARY_SUPPLEMENT

Fructose and galactose

10g galactose (mostly from lactose) plus 40g of fructose (free and bound, max amount of fructose from added free sugar/saccharose 25g)

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • University Hospital Freiburg

    collaborator OTHER

  • University Hospital Heidelberg

    collaborator OTHER

  • Medical University Innsbruck

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Michel Hochuli, MD, PhD · Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-24
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06852612 on ClinicalTrials.gov